This study identified a novel HBx genotype (HBx-E2) that results in a loss of proliferation promotion function and suggests a potential marker to preoperatively predict the prognosis of patients with BCLC stage B HBV-related HCC. Mechanistically, HBx-E2 lost its proliferation-promoting function in HCC cells and normal hepatocytes and failed to activate the JAK1 / STAT3 / STAT5 pathway.

(Xu QG et al. – Journal of Hepatology, 14 January 2019)

Read more